Business Context and Reporting Period
This Form 8-K Current Report was filed by MRI Interventions, Inc. (not Clearpoint Neuro, Inc.) on July 6, 2012, covering events occurring on July 2 and July 3, 2012. The filing details a private placement financing transaction involving the issuance of common stock and warrants to accredited investors.
Key Financial Metrics
- Gross Proceeds: Approximately $6.0 million raised from the sale of securities.
- Securities Issued: Approximately 5.5 million shares of common stock and warrants to purchase approximately 2.7 million shares.
- Purchase Price: $1.10 per unit (one share of common stock plus one warrant to purchase 0.5 shares).
- Placement Agent Compensation: Approximately $0.5 million in cash commissions plus warrants to purchase approximately 0.4 million shares.
- Warrant Terms (Investors): Exercise price of $1.45 per share; 5-year term; includes cashless exercise feature.
- Warrant Terms (Placement Agents): Exercise price of $1.10 per share; same terms as investor warrants otherwise.
Material Changes
The primary material change is the completion of the Financing Transaction, which increased the company's cash liquidity by $6.0 million and expanded its outstanding share count and potential dilution through the issuance of new stock and warrants. The filing does not provide comparative financial data (revenue, profit, or margins) for prior periods as this is a transaction-specific report.
Guidance, Outlook, and Risks
- Registration Rights: The Company is obligated to file a registration statement with the SEC within 45 calendar days of the final closing to allow investors to resell their shares.
- Liquidated Damages: The Company faces potential liquidated damages if the registration statement is not filed by the deadline, not declared effective within 90 days (or 120 days if reviewed by the SEC), or if effectiveness is not maintained.
- Future Participation: Investors purchasing at least $0.2 million of securities have the right to participate in certain future offerings for one year.
- Unusual Items: The transaction included a "cashless exercise" feature for warrants, allowing investors to exercise without cash payment under specific terms.
Investor Verification Checklist
- Verify the exact number of shares issued and the total dilution impact on existing shareholders.
- Confirm the filing date and effectiveness status of the required Registration Statement to assess potential liquidated damages.
- Review the full text of the Securities Purchase Agreement and Warrant forms (Exhibits 10.1, 10.2, and 4.1) for specific adjustment provisions and anti-dilution terms.
- Assess the company's use of the $6.0 million proceeds relative to its current cash burn rate and operational runway.